NL-OMON24699
Recruiting
Not Applicable
Efficacy and safety of eslicarbazepine acetate as therapy in patients with fibromyalgia: a double-blind, randomized, placebo-controlled, parallel-group, multicentre clinical trial.
BIAL - Portela & Ca, S.A.À Av. da Siderurgia Nacional4745 457 S. Mamede do CoronadoPortugalPhone: +351-229866100Fax: +351-229866192http://www.bial.com.0 sites480 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- BIAL - Portela & Ca, S.A.À Av. da Siderurgia Nacional4745 457 S. Mamede do CoronadoPortugalPhone: +351-229866100Fax: +351-229866192http://www.bial.com.
- Enrollment
- 480
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •Main Inclusion Criteria at V1:
- •1\. Patient is male or female, aged 18 or older;
Exclusion Criteria
- •Main Exclusion Criteria:
- •1\. Patient has any of the following: an inflammatory muscle or rheumatologic disease other than FMS; multiple sclerosis; active infections; untreated endocrine disorders; uncontrolled hypo or hyper thyroidism of any type;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Efficacy and safety of Eslicarbazepine Acetate (BIA 2-093) as single therapy for patients with newly diagnosed partial-onset seizures - ESL extension studyEpilepsyG40.0G40.1G40.2RBR-93gkd4Instituto de Neurologia de Curitiba
Completed
Phase 3
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial SeizuresHealth Condition 1: null- Partial EpilepsyCTRI/2011/04/001686Bial Portela C SA615
Active, not recruiting
Phase 1
Eslicarbazepine Acetate (BIA 2-093) as Therapy for Refractory Partial Seizures in Childrechildren and adolescents with refractory partial epileptic seizuresMedDRA version: 14.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2007-001887-55-ATBIAL - Portela & Ca, S.A.315
Active, not recruiting
Phase 1
Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as monotherapy for patients with newly diagnosed partial-onset seizures - open label extension study with eslicarbazepine acetateAdult patients with recently diagnosed partial-onset seizuresMedDRA version: 21.1Level: LLTClassification code 10065336Term: Partial epilepsySystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2015-001243-36-ITBIAL-PORTELA & Cª, S.A.207
Active, not recruiting
Phase 1
Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children: a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trialEUCTR2007-001887-55-GBBIAL - Portela & Ca, S.A.304